Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Quest Diagnostics reports Q3 2026 results on October 22 against a backdrop of steadily retreating short interest and an analyst consensus that has spent the past three months nudging targets higher without committing to a buy.
Options positioning has shifted notably less defensive into this print. The put/call ratio dropped to 0.94 last week, well below its 20-day average of 1.05, placing it half a standard deviation beneath normal levels. That marks a clear reversal from late September and early October, when the PCR ran as high as 1.37. The shift coincides with a 1.7% one-day dip to $235 on Friday, leaving the stock down nearly 5% on the month. Short interest reinforces the calmer tone: bears have been exiting positions for weeks, with the float short falling 25% over the past month to 2.66% of free float. Borrow conditions add nothing to the bear case. Availability is the loosest it has been in a year at 1,519%, and the cost to borrow has dropped 26% in the past week to 0.42% annually. This is not a stock the lending market is treating as a contested name.
The analyst debate centres on volume quality rather than growth direction. Bulls point to the July quarter, which saw revenue reach $2.81 billion, up 7.1% year-on-year, with the consumer-initiated testing platform alone generating close to $250 million and growing 35%. That result prompted a wave of target increases across Barclays, JPMorgan, UBS, Mizuho and others, all of which held their ratings while marking up numbers. Barclays, the most constructive voice on the Street with an Overweight, lifted its target to $260 earlier this month. The consensus mean sits at $251.40 against a current price of $235, implying the Street believes in modest upside but won't push the conviction button. Bears focus on a structural drag: revenue per requisition ran below expectations last quarter due to lower volumes from Corewell and Fresenius, and management has flagged pricing for 2026 as essentially flat. At 19.8 times trailing earnings and 12.4 times EV/EBITDA, DGX is not cheap enough to absorb a second consecutive miss on per-unit economics without a re-rating.
One ownership signal is worth noting. Insider activity over the past 90 days has been entirely one-directional, a net disposal of around 34,000 shares worth roughly $8.3 million. The CEO sold 10,000 shares at $242.72 on September 1, and the general counsel sold a combined $5.4 million in late August. All transactions were conducted under pre-arranged 10b5-1 plans, which reduces their informational value as conviction signals. T. Rowe Price filed a 13G/A in August showing its stake trimmed from 6.5% to 4.9%, no longer a 5%-threshold holder. BlackRock and the Vanguard entities remain the largest institutional holders and each added modestly in the most recent reporting period.
The closest peer, LH, fell 2.2% on Friday alongside DGX, suggesting broader sector pressure rather than DGX-specific concern. The October 22 print will test whether the sequential improvement in volume trends and consumer testing momentum is durable enough to justify the current multiple given the ongoing drag from key account pricing.
See the live data behind this article on ORTEX.
Open DGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
